- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06497504
Untersuchung von Bepirovirsen bei Teilnehmern, die mit dem humanen Immundefizienzvirus und einer chronischen Hepatitis-B-Virusinfektion leben (B-Fokus) (B-Focus)
Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie zur Bewertung der Wirksamkeit und Sicherheit der Behandlung mit Bepirovirsen bei Teilnehmern, die mit dem humanen Immundefizienzvirus und einer chronischen Hepatitis-B-Virusinfektion unter antiretroviraler Behandlung leben
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Almagro, Argentinien, C1427CEA
- GSK Investigational Site
-
Buenos Aires, Argentinien, 1023
- GSK Investigational Site
-
Buenos Aires, Argentinien, C1425AGC
- GSK Investigational Site
-
Buenos Aires, Argentinien, C1181ACI
- GSK Investigational Site
-
La Plata, Argentinien, B1900AVG
- GSK Investigational Site
-
Rosario, Argentinien, S2002KDR
- GSK Investigational Site
-
-
-
-
-
Aracaju, Brasilien, 49060-010
- GSK Investigational Site
-
Campinas, Brasilien, 13034-685
- GSK Investigational Site
-
Curitiba, Brasilien, 80810-050
- GSK Investigational Site
-
Manaus, Brasilien, 69040-000
- GSK Investigational Site
-
Salvador, Brasilien, 40110-060
- GSK Investigational Site
-
São Paulo, Brasilien, 04121-000
- GSK Investigational Site
-
-
-
-
-
Marseille, Frankreich, 13003
- GSK Investigational Site
-
Melun, Frankreich, 77000
- GSK Investigational Site
-
Montpellier, Frankreich, 34295
- GSK Investigational Site
-
Nantes, Frankreich, 44093
- GSK Investigational Site
-
Paris, Frankreich, 75018
- GSK Investigational Site
-
Paris, Frankreich, 75012
- GSK Investigational Site
-
-
-
-
-
Genova, Italien, 16132
- GSK Investigational Site
-
Milan, Italien, 20157
- GSK Investigational Site
-
Milan, Italien, 20162
- GSK Investigational Site
-
Naples, Italien, 80131
- GSK Investigational Site
-
Roma, Italien, 00153
- GSK Investigational Site
-
Sassari, Italien, 07100
- GSK Investigational Site
-
-
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- GSK Investigational Site
-
Toronto, Ontario, Kanada, M5G 1K2
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H2L 4P9
- GSK Investigational Site
-
Montreal, Quebec, Kanada, H4A 3J1
- GSK Investigational Site
-
Québec, Quebec, Kanada, G1V 4G2
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08036
- GSK Investigational Site
-
Córdoba, Spanien, 14004
- GSK Investigational Site
-
Madrid, Spanien, 28041
- GSK Investigational Site
-
Madrid, Spanien, 28040
- GSK Investigational Site
-
Madrid, Spanien, 28046
- GSK Investigational Site
-
Madrid, Spanien, 28031
- GSK Investigational Site
-
-
-
-
-
Ekurhuleni, Südafrika, 1459
- GSK Investigational Site
-
Johannesburg, Südafrika, 2092
- GSK Investigational Site
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Südafrika, 4052
- GSK Investigational Site
-
-
-
-
-
Banchiau Taipei, Taiwan, 220
- GSK Investigational Site
-
Kaohsiung City, Taiwan, 813
- GSK Investigational Site
-
-
-
-
California
-
Bakersfield, California, Vereinigte Staaten, 93301
- GSK Investigational Site
-
San Francisco, California, Vereinigte Staaten, 94115
- GSK Investigational Site
-
-
Florida
-
Orlando, Florida, Vereinigte Staaten, 32803-1851
- GSK Investigational Site
-
West Palm Beach, Florida, Vereinigte Staaten, 33409
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- GSK Investigational Site
-
-
New Jersey
-
Hillsborough, New Jersey, Vereinigte Staaten, 08844
- GSK Investigational Site
-
-
-
-
-
Bristol Avon, Vereinigtes Königreich, BS10 5NB
- GSK Investigational Site
-
London, Vereinigtes Königreich, E1 1BB
- GSK Investigational Site
-
London, Vereinigtes Königreich, SE5 9RS
- GSK Investigational Site
-
London, Vereinigtes Königreich, NW3 2QG
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Documented chronic hepatitis B virus (HBV) infection and documented human immunodeficiency virus (HIV)-1 infection greater than equal to (>=) 12 months prior to Screening.
-
Must be on uninterrupted antiretroviral therapy (ART) containing at least tenofovir disoproxil (TDF) or tenofovir alafenamide (TAF) plus lamivudine (3TC) or emtricitabine (FTC) for greater than (>)12 months, with no planned changes to the stable regimen over the duration of the study.
o Switch in ART is permitted >=6 months prior to Screening for reasons not related to loss of HIV or HBV control (e.g., change in formulary, tolerability, side effects).
-
Documented evidence of at least 2 plasma HIV-1 ribonucleic acid (RNA) measurements less than (<) 50 copies per milliliter (copies/mL) are required in the 12 months prior to Screening: 1 within 6 to 12 months prior to Screening and 1 within 6 months prior to Screening.
-
Plasma or serum HBV deoxyribonucleic acid (DNA) concentration must be adequately suppressed, defined as plasma or serum HBV DNA <90 international units per milliliter (IU/mL).
-
Plasma or serum HBsAg concentration >100 IU/mL and <=3000 IU/mL.
-
Plasma HIV-1 RNA concentration must be undetectable, defined as plasma HIV 1 RNA <50 copies/mL.
-
Cluster of differentiation 4 (CD4) count >=350 cells per cubic millimeter (cells/mm^3).
-
Alanine aminotransferase (ALT) <=2 times upper limit of normal (ULN).
Exclusion Criteria:
-
History of or suspected liver cirrhosis and/or evidence of cirrhosis.
-
Diagnosed or suspected hepatocellular carcinoma (HCC).
-
History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
-
Coinfection with:
-
Hepatitis C virus (HCV) with positive HCV antibody and detectable HCV RNA at Screening.
I. HCV treatment should have completed >12 months prior to Screening.
-
Hepatitis D virus (HDV) defined as positive or equivocal HDV antibody regardless of HDV RNA level.
-
-
Clinically significant abnormalities, aside from HIV-1 infection and chronic HBV infection in medical history (e.g., moderate severe liver disease other than chronic HBV/HIV, acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis coagulopathy) or clinically significant physical examination findings.
-
Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded unless they complete treatment during the Screening period and 7 days prior to randomization.
-
History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
-
History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause), current or history of an autoimmune condition or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
-
Participants who in the investigator's judgment, have a significant risk of suicide or self-harm.
-
Alcohol or drug abuse/dependence
-
Currently taking, or took within 3 months of Screening, any immunosuppressing drugs (e.g., prednisone), other than a short course of therapy (<=2 weeks) or topical/inhaled steroid use.
-
Participants to whom immunosuppressive treatment, including therapeutic doses of steroids, is contraindicated should not be considered for enrolment in the study.
-
Currently taking, or has taken within 12 months of Screening, any interferon containing therapy.
-
Participants requiring anti coagulation therapies (e.g., warfarin, Factor Xa inhibitors) or anti platelet agents (including but not limited to clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of study intervention, by the discretion of the investigator. Occasional use is permitted.
-
Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
-
Prior treatment with any oligonucleotide or small interfering ribonucleic acid (siRNA) within 12 months prior to the first dosing day.
-
Prior treatment with bepirovirsen.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Participants receiving Bepirovirsen
Participants will receive bepirovirsen. |
Bepirovirsen will be administered. |
|
Placebo-Komparator: Participants receiving Placebo
Participants will receive placebo. |
Placebo will be administered. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication
Zeitfenster: At study week 60
|
HBV virologic response defined as HBV surface antigen (HBsAg) not detected and HBV deoxyribonucleic acid (DNA) less than (<) lower limit of quantification (LLOQ). |
At study week 60
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of participants achieving HBV virologic response at the scheduled end of study treatment in absence of rescue medication
Zeitfenster: At study week 24
|
HBV virologic response defined as HBsAg not detected and HBV DNA <LLOQ. |
At study week 24
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: GSK Clinical Trials, GlaxoSmithKline
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Durch Blut übertragene Infektionen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des Immunsystems
- Infektionen
- RNA-Virusinfektionen
- Viruserkrankungen
- Erkrankungen des Verdauungssystems
- Leberkrankheiten
- Hepatitis, viral, menschlich
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- DNA-Virusinfektionen
- Langsame Viruserkrankungen
- Hepadnaviridae-Infektionen
- Hepatitis
- HIV-Infektionen
- Erworbenes Immunschwächesyndrom
- Hepatitis B
Andere Studien-ID-Nummern
- 219231
- 2023-509588-25 (Andere Kennung: EU CT Number)
- 2023 (US NIH Stipendium/Vertrag)
- 2023-509588-25-00 (Registrierungskennung: CTIS (EU))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD-Sharing-Zeitrahmen
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD-Sharing-Zugriffskriterien
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .